News & Updates

Patients with moderate-to-severe Crohn’s disease (CD) with delayed response to adalimumab or ustekinumab display similar 1-year clinical outcomes to those with an early response, reports a study.

Among people who have undergone stone surgery, those with a history of bowel resection and bypass appear to be at increased risk of repeat stone surgery, according to a study.

The novel endoscopic ultrasound (EUS)-guided gastroenterostomy (GE) is effective in patients with either a malignant or a benign disease, reports a study. In addition, adverse events are similar in both groups.

The combination regimen comprising sotorasib and panitumumab demonstrates a trend towards an improvement in overall survival (OS) compared with investigator’s choice of therapy among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) who had progressed on systemic therapy, according to the OS analysis of the CodeBreak 300 trial presented at ASCO 2024.

Treatment with vonoprazan, a potassium competitive acid blocker (P-CAB), successfully starts and sustains the healing of Los Angeles (LA) grade C/D esophagitis as compared with proton pump inhibitor (PPI) and has moderate short- and long-term safety, according to a study. On the other hand, other P-CAB therapies need more evidence to prove their advantages.